A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS study

Mikio Sugimoto1,*, Yoshiyuki Kakehi2, Shigeo Horie3, Yoshihiko Hirao4, and Hideyuki Akaza5

1Department of Urology, Kagawa University Faculty of Medicine, Kagawa, Japan, 2Kagawa University, Kagawa, Japan, 3Department of Urology, Juntendo University Faculty of Medicine, Tokyo, Japan, 4Osaka Gyoumeikan Hospital, Osaka, Japan, and 5Interfaculty Initiative in Information Studies, Graduate School of Interdisciplinary Information Studies, The University of Tokyo, Tokyo, Japan

*For reprints and all correspondence: Mikio Sugimoto, Department of Urology, Kagawa University Faculty of Medicine, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, Japan. E-mail: sugimoto.mikio@kagawa-u.ac.jp

Received 14 July 2021; Editorial Decision 24 September 2021; Accepted 29 September 2021

Abstract

Objectives: This study was conducted to evaluate the effect of low-dose chlormadinone acetate, an antiandrogen agent, on the persistence rate of active surveillance in patients with low-risk prostate cancer.

Methods: The study was a multicenter, placebo-controlled, double-blind, randomized controlled trial conducted at 38 sites in Japan. Low-risk prostate cancer patients were randomly assigned to the chlormadinone group or the placebo group and the persistence rate of active surveillance was evaluated for 3 years.

Results: Seventy-one patients in the chlormadinone group and 72 patients in the placebo group were analyzed. The persistence rate of active surveillance [95% CI] at 3 years was 75.5% [62.5–84.6] in the chlormadinone group and 50.1% [36.7–62.2] in the placebo group, showing a significant difference between the groups (P = 0.0039). The hazard ratio [95% CI] of the chlormadinone group to the placebo group for discontinuation of active surveillance was 0.417 [0.226–0.770]. The chlormadinone group showed a significant decrease in prostate specific antigen level, testosterone level and prostate volume. The number of positive cores at 12 and 36 months biopsy was significantly lower in the chlormadinone group. The incidence of adverse events was 43.7% in the chlormadinone group and 12.5% in the placebo group. The most common adverse event in the chlormadinone group was constipation in 22.5%, followed by hepatobiliary disorders in 9.9%.

Conclusions: In patients with low-risk prostate cancer, low-dose chlormadinone showed a reduced number of positive cores and prostate volume, and an increased persistence rate of active surveillance (UMIN000012284).

Key words: active surveillance, chlormadinone acetate, persistence rate, prostate cancer, QOL
Introduction

Prostate cancer (PC) is the second most common cancer next to lung cancer in men, with 1.27 million new cases worldwide and 339,000 deaths in 2018 (1,2). Despite the high incidence, most of patients with early stage PC show slow progression and good prognosis, and the 5-year survival rates for PC were 98% in the USA, 83% in Europe and 99% in Japan (3–5). In addition, the frequency of prostate latent cancer was 19.9% in Asians, 26.7% in Caucasians and 26.2% in Blacks (6). These cancers develop slowly, often over decades, and therefore, the patients may die of other causes without PC being found. Treatments for PC include surgery, radiation therapy, focal therapy, pharmacotherapy (hormonal therapy, chemotherapy, etc.) and active surveillance (AS) (7). Radical prostatectomy (RP) has been reported to have better overall and cancer-specific survival compared with watchful waiting and hormone therapy in randomized controlled trials (8,9). However, RP is an invasive treatment and can have sequelae that affect quality of life (QOL) such as post-operative complications, urinary incontinence and erectile dysfunction. Venderbos et al. (10) reported that patients with low-risk PC who had undergone AS had significantly better QOL for urinary function, urinary incontinence and sexual function compared with those who had undergone RP. Furthermore, AS also plays an important role in avoiding overtreatment of PC (11,12). In the USA, the proportion of treatment for localized PC was 47.9% for RP and 8.1% for AS in 2010, but in 2015, RP had decreased to 44.0% and AS had increased to 15.8% (13). According to data from Nara, Japan, the proportion of treatment for low-risk PC was 42.4% for RP and 7.1% for AS in 2004–06, and in 2010–13, RP had decreased to 29.0% and AS had increased to 18.2% (14).

In the long-term follow-up of AS in low-risk PC patients, the rate of discontinuing AS due to cancer progression and switching to other treatments was reported to be about 50% at 10 years (15). Persistence of AS is beneficial for patient QOL; however, the effect of pharmacotherapy on persistence of AS has not been fully investigated.

Chlormadinone acetate (chlormadinone) is an oral antiandrogen agent launched in Japan in 1981 and is indicated for benign prostatic hyperplasia and PC. Chlormadinone has been reported to have anti-cancer effects (16) in untreated PC patients, a complete response was found in 45.2% and a partial response was found in 33.3% according to clinical efficacy criteria reported by Shida et al. (17,18). Regarding benign prostatic hyperplasia, chlormadinone has been reported to reduce prostate specific antigen (PSA) level, testosterone level and prostate volume, as well as improved QOL for urinary function (19,20). These effects of chlormadinone may slow the progression of PC and improve the persistence rate of AS. Against this background, we conducted this study to investigate the effect of low-dose chlormadinone on the persistence rate of AS and its safety during long-term administration in patients with low-risk PC.

Patients and methods

Design

This study was a multicenter, placebo-controlled, double-blind, randomized controlled trial conducted at 38 sites in Japan from November 2013 to December 2019. This study was registered in University Hospital Medical Information Network—Clinical Trial Registry (UMIN-CTR) (UMIN000012284). Patients who met the eligibility criteria and did not meet the exclusion criteria were enrolled and randomly assigned by the enrollment center to the chlormadinone group or the placebo group. The assigned treatment group was concealed until the data were fixed for analysis. The target number of cases in each of the chlormadinone and placebo groups was 110, and the observation period was set to be 3 years. Randomization was performed using a minimization method with age, prostate volume, I-PSA, α1-blocker/anticholinergic agent use and facility as allocation factors. Among the enrolled patients, those who received treatment indicated in the protocol were defined as the full analysis set and were included in the analysis.

This study was conducted in accordance with the ethical principles of the Declaration of Helsinki (revised October 2013) and the Ethical Guidelines for Medical and Health Research Involving Human Subjects established by the Ministry of Health, Labor, and Welfare in Japan. The investigator provided sufficient explanation to the patients before obtaining written informed consent. The study protocol was approved before enrollment in the ethics committee in all study sites.

Intervention

In Japan, chlormadinone is indicated for PC and benign prostate hyperplasia, and the approved doses are 100 mg/day for PC and 50 mg/day for benign prostatic hyperplasia. In this study, a low dose of 50 mg (2 × 25-mg tablets) of chlormadinone, corresponding to the dose for benign prostatic hyperplasia, was used. Patients in each group were administered chlormadinone or placebo twice daily for 3 years. During the study period, treatments for PC (surgical therapy, radiation therapy, hormone therapy or chemotherapy) other than those indicated in the protocol of this study were prohibited. Treatment with another antiandrogen agent or a 5α-reductase inhibitor (5αRI) or any invasive treatment for benign prostatic hyperplasia was also prohibited. Treatment with α1-blockers and anticholinergic agents for benign prostatic hyperplasia or difficulty in urination was allowed if necessary.

Endpoints

The primary endpoint for efficacy was the AS persistence rate. Criteria for discontinuation of AS were defined as any of the following. (i) Disease progression such as a Gleason score ≥7, stage T2a, metastasis or increased tumor volume. If there was a clear deterioration in PSA levels or tumor markers (PSA doubling time or PAS density), disease progression was assessed by prostate biopsy, digital rectal examination or ultrasound/imaging. (ii) Onset of difficulty in urination or urinary symptoms requiring invasive treatment. (iii) Cases for which the investigator determines that second-line treatment for PC or benign prostatic hyperplasia is needed.

The secondary endpoints for efficacy were changes in PSA level, total testosterone level and Gleason score as an indicator of tumor progression. In addition, the rate of no cancer detected, prostate volume and the numbers of biopsy and positive cores were evaluated. Prostate volume was measured using transrectal or transabdominal ultrasound. For prostate biopsy, at least 6 sites of tissue were obtained by transrectal ultrasound-guided systematic biopsy. In this study, pathological diagnosis were performed at each institution according to the standardized criteria. The study schedule is shown in Fig. 1. QOL was evaluated using a domain summary score and domain-specific subscale of the Expanded Prostate Cancer Index Composite (EPIC). For the safety evaluation, adverse events (AEs) were collected in accordance with Common Terminology Criteria for Adverse Events ver. 4.0.
Study subjects
This study enrolled patients who met the eligibility criteria and did not meet any of the exclusion criteria. The eligibility criteria for patients were as follows: (i) diagnosed with PC by histological examination (biopsy), (ii) T1c, N0, M0, Gleason score ≤ 6 and PSA ≤ 10 ng/mL, (iii) having untreated PC, (iv) within 6 months of starting AS, if already undergone AS, (v) age ≥ 65 years old at enrollment, (vi) ECOG PS 0 or 1 and (vii) submission of written informed consent. The exclusion criteria for patients were as follows: (i) active double cancer, (ii) serious hepatic disorder, serious hepatic disease or serious disease (e.g., chronic renal failure, heart failure, myocardial infarction within 3 months of onset), (iii) serious drug allergy/hypersensitivity, (iv) active lower urinary tract symptoms (LUTS) requiring surgical treatment, (v) severe pain due to prostatitis, (vi) history of prostate surgery, (vii) not expected to survive for more than 5 years and (x) judged to be unsuitable by investigator.

Statistics
In a previous report of AS in low-risk PC patients, disease progression was found in 48% of patients in the placebo group at 3 years (21), and thus, the persistence rate of AS in the placebo group after 3 years was assumed to be 50%. Chlormadinone has been shown to suppress the progression of PC for an average of 35.6 months (16) and has been reported to be effective in 88.9% of patients with PC (17). Based on these results, the persistence rate of AS after 3 years in the chlormadinone group was assumed to be 70%. The number of cases required under the conditions of \( \alpha = 0.05 \) (type 1 error) and power 0.80 was estimated to be 93 cases for each group, and therefore, the number of cases in each group was set to be 110 cases in consideration of unevaluable cases.

The AS persistence rate was estimated using the Kaplan–Meier method, and the log-rank test was used for comparison between groups. The t-test was used to compare PSA levels, testosterone levels, prostate volumes and EPIC scores between groups. The Wilcoxon test was used to evaluate the distribution of Gleason score between groups. The significance level was set to be \(< 0.05\) on both sides.
Table 1. Patient characteristics

|                          | Chlormadinone (n = 71) | Placebo (n = 72) | P   |
|--------------------------|------------------------|-----------------|-----|
| Age (years old), median [IQR] | 70.0 [67.0, 75.0]     | 71.0 [67.0, 74.5] | 0.6692 |
| Body weight (kg), mean ± SD | 64.9 ± 9.3            | 64.4 ± 9.5      | 0.747 |
| ECOG PS, n (%)           |                        |                 |     |
| 0                       | 68 (95.8%)             | 66 (91.7%)      | 0.4936 |
| 1                       | 3 (4.2%)               | 6 (8.8%)        |     |
| TNM classification       |                        |                 |     |
| T1c                     | 71 (100.0%)            | 72 (100.0%)     | -   |
| N0                      | 71 (100.0%)            | 72 (100.0%)     | -   |
| M0                      | 71 (100.0%)            | 72 (100.0%)     | -   |
| Gleason score, n (%)     |                        |                 |     |
| 5                       | 5 (7.0%)               | 3 (4.2%)        | 0.4936 |
| 6                       | 66 (93.0%)             | 69 (95.8%)      |     |
| Number of biopsy core, median [IQR] | 12 [10, 12] | 12 [10, 16] | 0.1291 |
| Prostate volume, n (%)   |                        |                 |     |
| < 30 mL                 | 31 (43.7%)             | 32 (44.4%)      | 1.000 |
| ≥ 30 mL                 | 40 (56.3%)             | 40 (55.6%)      |     |
| Complication, n (%)      |                        |                 |     |
| No                      | 17 (23.9%)             | 16 (22.2%)      | 0.8447 |
| Yes                     | 54 (76.1%)             | 56 (77.8%)      |     |
| Concomitant drug, n (%)  |                        |                 |     |
| No                      | 19 (26.8%)             | 12 (16.7%)      | 0.16 |
| Yes                     | 52 (73.2%)             | 60 (83.3%)      |     |
| History of prostate treatment, n (%) | 65 (91.5%) | 66 (91.7%) | 1.000 |
| No                      | 6 (8.5%)               | 6 (8.3%)        |     |

ECOG PS, eastern cooperative oncology group performance status; IQR, interquartile range; SD, standard deviation.

Results

Patient characteristics

One hundred forty seven patients with PC were enrolled and 74 were assigned to the chlormadinone group and 73 to the placebo group (Fig. 2). Three cases in the chlormadinone group (not taking drug, n = 2; ineligible case, n = 1) and 1 case in the placebo group (no visit, n = 1) were excluded. Finally, 71 cases in the chlormadinone group and 72 cases in the placebo group were analyzed. There were no differences in patient characteristics including age, TNM classification, Gleason score and prostate volume between the two groups (Table 1).
Endpoints

Primary endpoint. In the chlormadinone group, AS was discontinued in 15 of 71 (21.1%) patients due to PC progression. In the placebo group, AS was discontinued in 35 of 72 (48.6%) patients because of PC progression in 32 patients and others in 3 patients. The AS persistence rate [95% CI] was 83.0% [71.4–90.2] in the chlormadinone group and 58.9% [46.3–69.6] in the placebo group at 2 years, and 75.5% [62.3–84.6] in the chlormadinone group and 50.1% [36.7–62.2] in the placebo group at 3 years, showing a significant difference between the two groups \((P = 0.0039)\) (Fig. 3). The hazard ratio [HR; 95%CI] for the chlormadinone group to the placebo group for discontinuation of AS was 0.417 [0.226–0.770].

Secondary endpoints. PSA levels were significantly lower in the chlormadinone group from 3 to 36 months and the difference between the two groups was \(\sim 4.0–5.5\) ng/mL throughout the study period (Fig. 4). Testosterone levels and prostate volume were significantly lower in the chlormadinone group at 12, 24 and 36 months compared with the placebo group (Table 2). The composition ratio of the Gleason score as tumor progression was significantly different between the groups at 12 months, but not at 36 months (Table 3). The rate for which no cancer detected was relatively high in the chlormadinone group at 12 months (60.9 vs. 30.2%) and 36 months (64.7 vs. 17.6%). No regional lymph node metastases or distant metastases were found in either group. There was no significant difference between the two groups in the number of biopsy cores at 12 and 36 months; however, the number of positive cores at 12 and 36 months was significantly lower in the chlormadinone group \((P = 0.0014\) and \(P = 0.0073)\).

QOL. The urinary summary EPIC score was significantly higher in the chlormadinone group at 36 months (Table 4). The sexual summary score was significantly lower in the chlormadinone group at 12 months, but there was no significant difference between the groups after 24 months. No differences were found in the other EPIC domain summary scores. Regarding the EPIC urinary subscale, the scores for function, burden, incontinence and irritation/obstruction at 36 months were all significantly higher in the chlormadinone group (Table 5). Regarding sexual subscales, the scores for the chlormadinone group were significantly lower after 12 months. Other EPIC domain-specific subscales did not differ between the two groups.

Safety. AEs were found in 43.7% (31/71) of the chlormadinone group and 12.5% (9/72) of the placebo group. Table 6 shows the AEs found in 3 or more patients in either group and serious AEs (SAEs). The most common AE in the chlormadinone group was constipation (22.5%, 16/71), followed by hepatobiliary disorders (9.9%, 7/71). SAEs were found in 5.6% (4/71) of the chlormadinone group and in 1.4% (1/72) of the placebo group. SAEs found in the chlormadinone group were malignant neoplasms, hepatobiliary disorders and hematomas.

Discussion

The overall survival rate with AS at 10 years was reportedly 93% in low-risk PC patients, suggesting that low-risk PC patients should undergo AS as a first-line treatment rather than aggressive curative therapy based on adequate risk assessment and life expectancy (15). In this study, low-dose chlormadinone was shown to prolong the persistence rate of AS (HR for discontinuation of AS [95% CI]: 0.417 [0.226–0.770]). In addition, the number of positive cores at 12 and 36 months was significantly lower in the chlormadinone group. These results suggest that antiandrogen therapy with low-dose chlormadinone may prolong the persistence rate of AS through suppression of PC progression. Since AS maintains the patient’s QOL compared with other treatments, prolongation of AS is considered to contribute to the prognosis of PC patients. In Japan, there are few reports of interventional studies on AS and, to our knowledge, this is the first report showing the effect of chlormadinone on the persistency of AS.

In our study, the rate of patients with no cancer detected at 36 weeks was higher in the chlormadinone group than in the placebo group (64.7 vs. 17.6%), but the rate of patients with a Gleason score of 7–8 did not show a clear differences between the groups (29.4 vs. 23.5%). Similar results have been reported with other drugs. Fleshner et al. (21) reported on the REDEEM study in which patients with PC undergoing AS were given dutasteride, a 5αRI, or placebo for 3 years, and the rate of PC progression was 48% in the placebo...
Table 2. Changes in testosterone level and prostate volume

|                          | Chlormadinone (n = 71) | Placebo (n = 72) | P     |
|--------------------------|------------------------|-----------------|-------|
| Testosterone level (ng/mL), mean ± SD |                        |                 |       |
| Pre-treatment            | 5.08 ± 2.00            | 5.60 ± 1.94     | 0.1273|
| 12 months                | 1.98 ± 0.82            | 5.65 ± 1.53     | <0.0001|
| 24 months                | 1.92 ± 0.82            | 5.66 ± 1.84     | <0.0001|
| 36 months                | 2.65 ± 1.53            | 5.42 ± 1.68     | <0.0001|
| Prostate volume (mL), mean ± SD |                      |                 |       |
| Pre-treatment            | 36.4 ± 17.2            | 35.3 ± 17.5     | 0.7079|
| 12 months                | 26.7 ± 13.3            | 34.1 ± 16.0     | 0.0147|
| 24 months                | 21.9 ± 14.0            | 35.1 ± 15.7     | 0.0008|
| 36 months                | 23.7 ± 10.9            | 39.0 ± 20.7     | 0.0049|

Table 3. Histological examination

|                          | Chlormadinone (n = 71) | Placebo (n = 72) | P     |
|--------------------------|------------------------|-----------------|-------|
| No. of patients biopsied, n (%) |                      |                 |       |
| Pre-treatment            | 71 (100.0%)            | 72 (100.0%)     | -     |
| 12 months                | 46 (64.8%)             | 43 (59.7%)      |       |
| 36 months                | 17 (23.9%)             | 17 (23.6%)      |       |
| Gleason score, score (%) |                        |                 |       |
| Pre-treatment            |                        |                 |       |
| No cancer detected       | 0                      | 0               | 0.459 |
| 5                       | 5 (7.0%)               | 3 (4.2%)        |       |
| 6                       | 66 (93.0%)             | 69 (95.8%)      |       |
| 7                       | 0                      | 0               |       |
| 8                       | 0                      | 0               |       |
| 12 months                |                        |                 |       |
| No cancer detected       | 28 (60.9%)             | 13 (30.2%)      | 0.0081|
| 5                       | 1 (2.2%)               | 2 (4.7%)        |       |
| 6                       | 14 (30.4%)             | 24 (55.8%)      |       |
| 7                       | 3 (6.5%)               | 3 (7.0%)        |       |
| 8                       | 0                      | 1 (2.3%)        |       |
| 36 months                |                        |                 |       |
| No cancer detected       | 11 (64.7%)             | 3 (17.6%)       | 0.1196|
| 5                       | 0                      | 0               |       |
| 6                       | 1 (5.9%)               | 10 (58.8%)      |       |
| 7                       | 4 (23.5%)              | 4 (23.5%)       |       |
| 8                       | 1 (5.9%)               | 0               |       |
| Number of biopsy cores, mean ± SD |                    |                 |       |
| Pre-treatment            | 11.9 ± 2.9             | 13.7 ± 6.8      | 0.0385|
| 12 months                | 12.1 ± 2.5             | 13.2 ± 4.7      | 0.17  |
| 36 months                | 12.4 ± 2.4             | 12.7 ± 2.2      | 0.6577|
| Number of positive cores, mean ± SD |                   |                 |       |
| Pre-treatment            | 1.4 ± 0.7              | 1.5 ± 0.9       | 0.384 |
| 12 months                | 0.7 ± 1.0              | 1.5 ± 1.4       | 0.0014|
| 36 months                | 0.5 ± 0.7              | 2.1 ± 2.3       | 0.0073|

group and 38% in the 5αRI group (P = 0.009). In the REDEEM study, the rate of patients with no cancer detected was relatively higher in the 5αRI group than in the placebo group (36 vs. 23%), but the rates of patients with a Gleason score of 7–8 were nearly the same (14 vs. 16%) (21). In addition, Murtola et al. (22) reported that antiandrogen therapy with 5αRI reduced the risk of PC for patients with a Gleason score of 2–6 (HR [95%CI]: 0.59 [0.38, 0.91]) but did not affect the risk of PC for patients with a Gleason score of 7–10 (1.33 [0.77, 2.30]). Furthermore, antiandrogen therapy with 5αRI lowers PSA levels in benign prostatic hyperplasia or low-grade PC but shows less PSA-lowering effects in high-grade PC (23,24). These findings suggest that antiandrogen therapy with 5αRI or chlormadinone can be expected to suppress the progression of low-grade PC but may have no or little effect on high-grade PC.
Even though antiandrogen therapy lowers PSA levels, it may possibly identify high-grade PC and, therefore, may prolong AS only for low-grade PC, which is a good indication for AS. However, the effects of antiandrogen therapy on the long-term prognosis need further investigation.

There are some differences between our study and the REDEEM study. The number of positive cores has been reported to affect the progression of PC in AS (15,25) and, in the REDEEM study, the percentage of positive cores at final biopsy was relatively lower in the αRI group than in the placebo group (13.9 vs. 19.0%), but this was not a significant difference (21). In our study, the number of positive cores in the chlormadinone group at 36 months was about one-fourth that of the placebo group (chlormadinone 0.5 ± 0.7 vs. placebo 2.1 ± 2.8, \( P < 0.0073 \)), which is a significant difference. In addition, the rate of no cancer detected at the final evaluation was 36% for 5αRI and 23% for placebo in the REDEEM study (21), and 64.7% for chlormadinone and 17.6% for placebo in our study, a rate more than three times higher than the placebo group. One of the causes of these differences may be differences in the target patients. Our study targeted only patients with a tumor class of T1c, whereas the REDEEM study included T1c-T2a patients (21). This suggests that anti-androgenic interventions during AS may be more effective in lower-risk PC populations. Another possible factor is due to the different properties of the drugs. Chlormadinone reduces both dihydrotestosterone (DHT) and testosterone levels, while 5αRI reduces DHT levels and increases testosterone levels (26). Dutasteride, a 5αRI, has been reported to have no significant reduction in prostate volume or PSA level in patients with small prostate volume (<40 mL) or low PSA (27). In another report, the rate of change in PSA level and prostate volume from chlormadinone has been shown to be unaffected by baseline PSA level and prostate volume (28). In the REDEEM study, the mean prostate volume in the 5αRI group was 43.2 mL, suggesting that it may have been a patient population in which the pharmacological effects of 5αRI were not strongly expressed. Furthermore, a non-clinical study showed that chlormadinone has a stronger prostate-reducing effect than 5αRI, and it has been suggested that the reason for the difference between the two drugs is that chlormadinone lowers both DHT and testosterone levels, while dutasteride lowers only DHT level (29). These results suggest that the lowering-DHT effect from dutasteride may be offset by the increase in testosterone level (26). Although the comparison between chlormadinone and 5αRI has not been fully investigated in clinical practice and needs further investigation, it is possible that the different pharmacological actions of the two drugs may have had an effect on the differences between the REDEEM study and this study.

Regarding QOL, the chlormadinone group had significantly higher scores for function, burden, incontinence and irritation/obstruction than the placebo group at 36 months. LUTS has been shown to affect anxiety in PC patients undergoing AS (30). The improvement of QOL in the chlormadinone group may be related to the improvement of LUTS because of the decrease in prostate volume. Regarding sexual subscales, the function score was significantly higher in the chlormadinone group at 36 months. LUTS has been shown to affect anxiety in PC patients undergoing AS (30). The improvement of QOL in the chlormadinone group may be related to the improvement of LUTS because of the decrease in prostate volume. Regarding sexual subscales, the function score was significantly lower in the chlormadinone group from 12 to 36 months. This was due to a decrease in testosterone levels caused by antiandrogen therapy and is a known effect of chlormadinone. In this study, the dosage of chlormadinone was set to be 50 mg/day, the dose for benign prostatic hyperplasia. PC is often accompanied by biliary disorders (9.9%). Chlormadinone has been used clinically in Japan since 1981, and the results of the safety evaluation in

| Table 4. QOL: EPIC domain summary scores |
|-----------------------------------------|
|                                        |
| **Urinary summary scores, mean ± SD**   |
| Baseline                                | 90.6 ± 7.3 | 91.1 ± 9.2 | 0.7225 |
| 12 months                               | 89.6 ± 10.1| 86.1 ± 10.5| 0.1310 |
| 24 months                               | 92.7 ± 7.4 | 88.3 ± 10.7| 0.0839 |
| 36 months                               | 94.2 ± 7.1 | 81.5 ± 15.0| 0.0027 |
| **Bowel summary scores, mean ± SD**     |
| Baseline                                | 93.6 ± 8.2 | 95.0 ± 6.2 | 0.2562 |
| 12 months                               | 93.8 ± 7.3 | 95.2 ± 5.3 | 0.3138 |
| 24 months                               | 93.3 ± 6.5 | 95.2 ± 8.8 | 0.3832 |
| 36 months                               | 96.2 ± 4.9 | 92.2 ± 8.4 | 0.1053 |
| **Sexual summary scores, mean ± SD**    |
| Baseline                                | 40.3 ± 12.9| 39.2 ± 12.4| 0.6252 |
| 12 months                               | 30.9 ± 10.6| 37.3 ± 9.4 | 0.0054 |
| 24 months                               | 31.7 ± 11.1| 33.6 ± 11.0| 0.5293 |
| 36 months                               | 30.3 ± 10.4| 36.3 ± 10.4| 0.1458 |
| **Hormonal summary scores, mean ± SD**  |
| Baseline                                | 93.3 ± 7.2 | 93.9 ± 6.1 | 0.6138 |
| 12 months                               | 93.3 ± 6.2 | 93.9 ± 5.7 | 0.6638 |
| 24 months                               | 93.1 ± 7.7 | 93.5 ± 5.0 | 0.8085 |
| 36 months                               | 93.3 ± 8.9 | 92.4 ± 7.3 | 0.7460 |
Table 5. EPIC domain-specific subscales

|                      | Chlormadinone (n = 71) | Placebo (n = 72) | P     |
|----------------------|------------------------|-----------------|-------|
| Urinary subscales, mean ± SD |                        |                 |       |
| Function             |                        |                 |       |
| Baseline             | 95.8 ± 7.4             | 95.6 ± 7.9      | 0.8899|
| 12 months            | 94.9 ± 10.7            | 90.4 ± 13.4     | 0.1017|
| 24 months            | 95.7 ± 8.0             | 92.7 ± 10.8     | 0.2355|
| 36 months            | 97.1 ± 5.4             | 86.6 ± 16.7     | 0.0161|
| Bother               |                        |                 |       |
| Baseline             | 88.6 ± 9.9             | 87.9 ± 12.0     | 0.6946|
| 12 months            | 85.8 ± 12.5            | 83.0 ± 11.7     | 0.2988|
| 24 months            | 90.5 ± 8.7             | 85.2 ± 12.4     | 0.0714|
| 36 months            | 92.1 ± 9.47            | 77.8 ± 16.2     | 0.0030|
| Incontinence         |                        |                 |       |
| Baseline             | 94.8 ± 11.5            | 94.2 ± 12.0     | 0.7908|
| 12 months            | 92.0 ± 17.2            | 89.5 ± 14.4     | 0.4810|
| 24 months            | 84.0 ± 12.1            | 89.8 ± 18.1     | 0.3153|
| 36 months            | 96.1 ± 7.3             | 85.3 ± 16.4     | 0.0159|
| Irritation/obstruction|                        |                 |       |
| Baseline             | 91.0 ± 7.6             | 91.0 ± 9.0      | 0.9889|
| 12 months            | 90.1 ± 8.5             | 86.1 ± 10.8     | 0.0659|
| 24 months            | 93.3 ± 5.7             | 89.6 ± 8.3      | 0.0614|
| 36 months            | 94.3 ± 7.7             | 81.1 ± 16.2     | 0.0038|
| Bowel subscales, mean ± SD |                        |                 |       |
| Function             |                        |                 |       |
| Baseline             | 92.3 ± 8.9             | 93.6 ± 8.1      | 0.3963|
| 12 months            | 92.9 ± 8.1             | 94.1 ± 7.1      | 0.4734|
| 24 months            | 89.9 ± 10.1            | 94.3 ± 9.8      | 0.1104|
| 36 months            | 93.7 ± 7.6             | 89.9 ± 10.8     | 0.2433|
| Bother               |                        |                 |       |
| Baseline             | 94.8 ± 9.2             | 96.4 ± 5.4      | 0.2189|
| 12 months            | 94.7 ± 7.2             | 96.4 ± 5.6      | 0.2462|
| 24 months            | 96.8 ± 7.1             | 96.1 ± 8.4      | 0.7405|
| 36 months            | 98.3 ± 3.6             | 94.4 ± 8.2      | 0.0750|
| Sexual subscales, mean ± SD |                        |                 |       |
| Function             |                        |                 |       |
| Baseline             | 21.9 ± 18.1            | 19.5 ± 16.7     | 0.4270|
| 12 months            | 9.2 ± 10.6             | 17.6 ± 14.3     | 0.0036|
| 24 months            | 9.5 ± 11.2             | 15.6 ± 11.0     | 0.0479|
| 36 months            | 6.8 ± 11.4             | 16.3 ± 15.4     | 0.0459|
| Bother               |                        |                 |       |
| Baseline             | 81.7 ± 23.1            | 83.6 ± 23.2     | 0.6331|
| 12 months            | 79.8 ± 29.9            | 81.7 ± 20.7     | 0.7487|
| 24 months            | 81.5 ± 28.6            | 74.0 ± 30.7     | 0.3528|
| 36 months            | 83.1 ± 30.8            | 81.3 ± 25.2     | 0.8474|
| Hormonal subscales, mean ± SD |                        |                 |       |
| Function             |                        |                 |       |
| Baseline             | 90.1 ± 11.2            | 91.3 ± 8.5      | 0.4891|
| 12 months            | 91.0 ± 9.7             | 92.2 ± 7.6      | 0.5319|
| 24 months            | 90.9 ± 11.7            | 91.4 ± 6.0      | 0.8313|
| 36 months            | 89.9 ± 14.3            | 90.9 ± 9.2      | 0.8049|
| Bother               |                        |                 |       |
| Baseline             | 96.1 ± 5.6             | 96.2 ± 5.3      | 0.9355|
| 12 months            | 95.3 ± 5.3             | 95.3 ± 5.5      | 0.9672|
| 24 months            | 94.9 ± 6.4             | 95.3 ± 5.5      | 0.8075|
| 36 months            | 96.1 ± 5.5             | 93.6 ± 9.4      | 0.3400|
this study were similar to the previously known safety profile. In this study, administration of chlormadinone showed reduced positive core count, improved urinary QOL and increased AS persistence in low-risk PC patients. When monitoring PSA, it is also necessary to consider the PSA-lowering effect of chlormadinone (32).

This study has the following limitations. This study only included patients aged ≥65 years old with clinical stage T1c, N0, M0 PC. The pathological diagnosis were performed at each institution. The pathological findings for the chlormadinone group were obtained from patients undergoing chlormadinone treatment, and the influence of chlormadinone on the Gleason score is unknown. The observation period was 3 years, and so longer term efficacy and safety are unknown. The results of this study need to be interpreted with these factors in mind.

In conclusion, in low-risk PC patients, low-dose chlormadinone reduced prostate volume, the number of positive cores and prolonged the persistence rate of AS while maintaining QOL. Our results showed that low-dose chlormadinone contributes to prolonged AS while maintaining QOL in patients with low-risk PC. However, the effects of chlormadinone on the long-term prognosis need further investigation.

Acknowledgements
We cordially thank deceased Dr Yasuo Ohashi of the former Professor of Chuo University for his valuable advice and contributions to the study conception and design, data acquisition, analysis and interpretation, and drafting the manuscript (Deceased March 2021). Medical writing assistance was provided by AMY information planning LLC., which was funded by Public Health Research Foundation. We are grateful to all the patients, investigators and clinical research coordinators who participated in this study.

Funding
This study was conducted by the Comprehensive Support Project for Oncology Research (CSPOR) of the Public Health Research Foundation and this work was supported by ASKA Pharmaceutical Company Limited. The funding company had no role in the data analysis nor the writing of this manuscript.

Conflicts of interest statement
None declared.

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
2. Rawla P. Epidemiology of prostate cancer. World J Oncol 2019;10:63–89.
3. SEER. Cancer Statistics Review, 1975-2015. https://seer.cancer.gov/csr/1975_2015/ (10 October 2020, date last accessed).
4. Epidemiology of prostate cancer in Europe [Internet]. European Commission, 2015. https://ec.europa.eu/jrc/en/publication/epidemiology-prostate-cancer-europe (10 October 2020, date last accessed).
5. Cancer Statistics in Japan. https://ganjoho.jp/reg_stat/statistics/stat/summary.html (10 October 2020, date last accessed).
6. Rebbeck TR, Haas GP. Temporal trends and racial disparities in global prostate cancer prevalence. Can J Urol 2014;21:7496–506.
7. Kakehi Y, Sugimoto M, Taoka R, Committee for Establishment of the Evidenced-Based Clinical Practice Guideline for Prostate Cancer of the Japanese Urological Association. Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition). Int J Urol 2017;24:648–66.
8. Bill-Axelson A, Holmberg L, Garino H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370:932–42.
9. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203–13.
10. Venderbos LDF, Aluwini S, Roobol MJ, et al. Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer. Qual Life Res 2017;26:1631–45.
11. Womble PR, Montie JE, Ye Z, et al. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. Eur Urol 2015;67:44–50.
12. Hirama H, Sugimoto M, Miyatake N, et al. Health-related quality of life in Japanese low-risk prostate cancer patients choosing active surveillance: 3-year follow-up from PRIAS-JAPAN. World J Urol 2021;39:2491–2497.
13. Mahal BA, Butler S, Franco I, et al. Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010-2015. JAMA 2019;321:704–6.
14. Tanaka N, Nakai Y, Miyake M, et al. Trends in risk classification and primary therapy of Japanese patients with prostate cancer in the long term. Jpn J Clin Oncol 2022;52:2.
Nara urological research and treatment group (NURTG) - comparison between 2004-2006, 2007-2009, and 2010-2012. **BMC Cancer** 2017;17:616.

15. Tosoian JJ, Mamawala M, Epstein JI, et al. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. **J Clin Oncol** 2015;33:3379–85.

16. Shida K, Tsuji I, Shimazaki J, et al. Clinical effect of chlormadinone acetate on prostate cancer. **Hinyokika Kiyo** 1980;26:1553–74 (in Japanese).

17. Fukuoka H, Goto A, Murai T, et al. Effect of chlormadinone acetate on prostate cancer. **Hinyokika Kiyo** 1986;32:1821–30 (in Japanese).

18. Shida K, Matsumoto K, Shimazaki J, Nishimura R, Takeuchi H, Seto T. Proposal of clinical efficacy criteria for anticancer drugs in prostate cancer. *Nihon Rinsho j urol* 1978;40:869–77 (in Japanese).

19. Shida K, Tsuji I, Shimazaki J, et al. Changes in serum PSA and testosterone levels in patients with benign prostatic hyperplasia due to chlormadinone acetate. **Hinyokika Kiyo** 1980;26:1553–74 (in Japanese).

20. Fujimoto K, Hirao Y, Ohashi Y, et al. The effects of chlormadinone acetate on lower urinary tract symptoms and erectile functions of patients with benign prostatic hyperplasia: a prospective multicenter clinical study. **Ther Adv Urol** 2013;2013:584678.

21. Fleshner NE, Lucia MS, Egerdie B, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. **Lancet** 2012;379:1103–11.

22. Murtola TJ, Tammela TL, Määtänniemi L, Ala-Opas M, Stenman UH, Auvinen A. Prostate cancer incidence among finasteride and alpha-blocker users in the Prostate Cancer Screening Trial. **Br J Cancer** 2009;101:843–8.

23. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. **J Natl Cancer Inst** 2006;98:1128–33.

24. Andriole GL, Bostwick D, Brawley OW, et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. **J Urol** 2011;185:126–31. Prostate cancer screening trial. **Br J Cancer** 2009;101:843–8.

25. Sugimoto M, Hiram H, Yamaguchi A, et al. Should inclusion criteria for active surveillance for low-risk prostate cancer be more stringent? From an interim analysis of RIAS-JAPAN. **World J Urol** 2015;33:981–7.

26. The MK-906 (finasteride) study group. One-year experience in the treatment of benign prostatic hyperplasia with finasteride. The MK-906 (finasteride) study group. **J Androl** 1991;12:372–5.

27. Lin VC, Liao CH, Wang CC, Kuo HC. 5α-reductase inhibitor is less effective in men with small prostate volume and low serum prostate specific antigen level. **J Formos Med Assoc** 2015;114:865–71.

28. Fujimoto K, Hirao Y, Ohashi Y, et al. Changes in serum prostate specific antigen and testosterone levels after chlormadinone acetate treatment in patients with benign prostatic hyperplasia: a prospective multicenter clinical study. **Hinyokika Kiyo** 2011;57:177–83 in Japanese.

29. Kobayashi H, Gotanda K, Shibata Y, Watanabe J, Nakano Y, Shinbo A, Suzuki K. Suppressing effects of the antiandrogen agent, chlormadinone acetate and the 5α-reductase inhibitor, dutasteride on prostate weight and intraprostatic androgen levels in rats. **Arzneimittelforschung** 2011;61:515–20.

30. Tan HJ, Marks LS, Hoyt MA, et al. The relationship between intolerance of uncertainty and anxiety in men on active surveillance for prostate cancer. **J Urol** 2016;195:1724–30.

31. Lepor H. Evaluating men with benign prostatic hyperplasia. **Rev Urol** 2004;6:58–515.

32. Fujimoto K, Hirao Y, Masumori N, et al. Prostate-specific antigen changes as a result of chlormadinone acetate administration to patients with benign prostatic hyperplasia: a retrospective multi-institutional study. **Int J Urol** 2006;13:543–9.